PARP1 and ovarian carcinoma: In human ovarian cancer tissue samples, expression of p-ALK was associated with resistance to PARP inhibitors (Fig. 1c) and platinum-based (cisplatin/carboplatin) chemotherapy (Fig. 1d, left panel).